R J St George1, J G Nutt, K J Burchiel, F B Horak. 1. Department of Neurology, Oregon Health & Sciences University, 505 NW 185 Avenue, Beaverton, OR 97006, USA. stgeorgr@ohsu.edu
Abstract
OBJECTIVE: Deep brain stimulation (DBS) alleviates the cardinal Parkinson disease (PD) symptoms of tremor, rigidity, and bradykinesia. However, its effects on postural instability and gait disability (PIGD) are uncertain. Contradictory findings may be due to differences the in stimulation site and the length of time since DBS surgery. This prompted us to conduct the first meta-regression of long-term studies of bilateral DBS in the subthalamic nucleus (STN) and globus pallidus interna (GPi). RESULTS: Eleven articles reported a breakdown of the Unified Parkinson's Disease Rating Scale score before and beyond 3 years postsurgery (mean 4.5 years). Random effects meta-regression revealed that DBS initially improved PIGD compared to the OFF medicated state before surgery, but performance declined over time and extrapolation showed subjects would reach presurgery levels 9 years postsurgery. ON medication, DBS improved PIGD over and above the effect of medication before surgery. Nevertheless, for the STN group, PIGD progressively declined and was worse than presurgery function within 2 years. In contrast, GPi patients showed no significant long-term decline in PIGD in the medicated state. Improvements in cardinal signs with DBS at both sites were maintained across 5 years in the OFF and ON medication states. CONCLUSIONS: DBS alone does not offer the same improvement to PIGD as it does to the cardinal symptoms, suggesting axial and distal control are differentially affected by DBS. GPi DBS in combination with levodopa seemed to preserve PIGD better than did STN DBS, although more studies of GPi DBS and randomized controls are needed.
OBJECTIVE: Deep brain stimulation (DBS) alleviates the cardinal Parkinson disease (PD) symptoms of tremor, rigidity, and bradykinesia. However, its effects on postural instability and gait disability (PIGD) are uncertain. Contradictory findings may be due to differences the in stimulation site and the length of time since DBS surgery. This prompted us to conduct the first meta-regression of long-term studies of bilateral DBS in the subthalamic nucleus (STN) and globus pallidus interna (GPi). RESULTS: Eleven articles reported a breakdown of the Unified Parkinson's Disease Rating Scale score before and beyond 3 years postsurgery (mean 4.5 years). Random effects meta-regression revealed that DBS initially improved PIGD compared to the OFF medicated state before surgery, but performance declined over time and extrapolation showed subjects would reach presurgery levels 9 years postsurgery. ON medication, DBS improved PIGD over and above the effect of medication before surgery. Nevertheless, for the STN group, PIGD progressively declined and was worse than presurgery function within 2 years. In contrast, GPipatients showed no significant long-term decline in PIGD in the medicated state. Improvements in cardinal signs with DBS at both sites were maintained across 5 years in the OFF and ON medication states. CONCLUSIONS: DBS alone does not offer the same improvement to PIGD as it does to the cardinal symptoms, suggesting axial and distal control are differentially affected by DBS. GPi DBS in combination with levodopa seemed to preserve PIGD better than did STN DBS, although more studies of GPi DBS and randomized controls are needed.
Authors: O Beauchet; C Annweiler; V Dubost; G Allali; R W Kressig; S Bridenbaugh; G Berrut; F Assal; F R Herrmann Journal: Eur J Neurol Date: 2009-03-31 Impact factor: 6.089
Authors: Luigi M Romito; Maria Fiorella Contarino; Nicola Vanacore; Anna Rita Bentivoglio; Massimo Scerrati; Alberto Albanese Journal: Mov Disord Date: 2009-03-15 Impact factor: 10.338
Authors: Frances M Weaver; Kenneth Follett; Matthew Stern; Kwan Hur; Crystal Harris; William J Marks; Johannes Rothlind; Oren Sagher; Domenic Reda; Claudia S Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff Bronstein; Gatana Stoner; Jill Heemskerk; Grant D Huang Journal: JAMA Date: 2009-01-07 Impact factor: 56.272
Authors: Jens Volkmann; Alberto Albanese; Jaime Kulisevsky; Aana-Lena Tornqvist; Jean-Luc Houeto; Bernard Pidoux; Anne-Marie Bonnet; Alexandre Mendes; Alim-Louis Benabid; Valerie Fraix; Nadege Van Blercom; Jing Xie; José Obeso; Maria Cruz Rodriguez-Oroz; Jurge Guridi; Alfons Schnitzler; Lars Timmermann; Alexandre A Gironell; Juan Molet; Benta Pascual-Sedano; Stig Rehncrona; Elena Moro; Anthony C Lang; Andres M Lozano; Anna Rita Bentivoglio; Massimo Scerrati; Maria Fiorella Contarino; Luigi Romito; Marc Janssens; Yves Agid Journal: Mov Disord Date: 2009-06-15 Impact factor: 10.338
Authors: Kévin Ahrweiller; J F Houvenaghel; A Riou; S Drapier; P Sauleau; C Haegelen; P Jannin; M Vérin; X Palard; F Le Jeune Journal: J Neurol Date: 2019-07-26 Impact factor: 4.849
Authors: Daniel S Peterson; Kristen A Pickett; Ryan P Duncan; Joel S Perlmutter; Gammon M Earhart Journal: Clin Neurophysiol Date: 2013-11-05 Impact factor: 3.708